People with rare diseases are at high risk for experiencing poor quality of life, including increased levels of anxiety, depression, pain, fatigue and limited ability to participate in society, a new study from an Oregon State University shows.
The study is believed to be the first large-scale study of adults living in the U.S. that are diagnosed with a rare disease or disorder, said Kathleen Bogart, an assistant professor of psychology in the College of Liberal Arts at OSU.
“These findings suggest that the quality of life needs of people with rare diseases are not being met and that more work is needed to provide psychosocial support for this group,” said Bogart, whose work focuses on the psychosocial implications of disability. “There is a disparity here and intervention is needed.”
The findings were published this month in Orphanet Journal of Rare Diseases. Veronica Irvin, an assistant professor in OSU’s College of Public Health and Human Sciences, co-authored the paper.
About 350 million people worldwide live with at least one rare disease, and there are about 7,000 diseases classified as rare because they affect small numbers of people. Rare is defined in the U.S. as fewer 200,000 Americans at one time; in Europe, fewer than 1 in 2,000 people.
The new paper is part of a larger, multi-part study, the Adults with Rare Disorders Support project, to assess the psychosocial support needs of people with a variety of rare diseases and disorders.
While each disease may have its own set of characteristics and health impacts, researchers have found that people with rare diseases often share similar characteristics and experiences – including little information or treatment, lengthy times to diagnosis and isolation. Because of this shared experience, they may also benefit from similar types of psychosocial supports, Bogart said.
“Even though their diseases are different, their experience is similar,” Bogart said. “There is some benefit to looking at this group collectively, rather than trying to work with each small rare disease group independently.”
For the study, researchers surveyed more than 1,200 U.S. residents with rare diseases, asking them to complete questionnaires about their disease and their quality of life.
The survey group represented 232 different rare diseases, including ataxia, Bell’s palsy, Ehlers Danlos syndrome, mast cell disorders and narcolepsy, and 13 percent of the group had more than one rare disease. The researchers also found that study participants waited on average nine years before receiving a correct diagnosis.
Compared to a representative sample of U.S. residents, people with rare diseases experienced worse anxiety than 75 percent of the population; worse depression than 70 percent of the population; worse fatigue than 85 percent of the population; worse pain than 75 percent of the population; worse physical functioning than 85 percent of the population and worse ability to participate in society than 80 percent of the population.
Those with rare diseases also had poorer quality of life than U.S. residents with common chronic conditions such as heart disease, diabetes or arthritis, Bogart said.
“There is something specific about having a ‘rare’ disease that contributes to poorer quality of life,” she said. “Many people struggle with getting an accurate diagnosis, which also can lead to a constant de-legitimization of their experience, with people wondering if it is ‘all in your head.'”
Study participants with systematic and rheumatic diseases had the poorest quality of life profiles, and those with neurological diseases also had very poor quality of life. People with developmental anomalies experienced fewer quality of life problems than the other groups.
The findings suggest that quality of life issues such as psychosocial support should receive more priority from organizations and funding agencies that support people with rare diseases and disorders, Bogart said. Supporting quality of life is especially important for people living with one of the 95 percent of rare disorders that have no effective treatments.
Including psychosocial support in organizational mission statements, providing psychosocial support through support groups or conferences and making funding for psychosocial support a priority could help address quality of life issues for people with rare diseases, in part by helping reduce stigma and isolation and improving access to information and treatments.
“Some people with rare diseases may never meet another person with that disease,” Bogart said. “That can be very isolating. Conferences are one way to bring people with similar experiences together to share. It helps them feel connected, normalized and validated.”
People with rare diseases who are experiencing poor quality of life also should seek support from a mental health professional, a rare disease group and/or peers with rare disorders, she said.
“The beauty of these quality of life of findings is that they are not disease-specific,” Bogart said. “There are already umbrella groups that can provide this kind of support to people with rare diseases, regardless of their individual diseases.”
Next, the researchers plan to meet with focus groups of participants from the first phase of the study to further explore quality of life issues. The goal is to identify effective supports and develop interventions that could help people with rare diseases improve their quality of life.
“We’d like to come up with a blueprint of ways for these support organizations to provide help,” Bogart said. “This is something we could do on a very broad level to help a lot of people and maximize the use of very limited resources.”